- 米国企業
- Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc.AVIR
時価総額
$3億
PER
2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | |
Collaboration revenue | 49 | 351 | - |
Research and development expense | 38 | 167 | 82 |
General and administrative | 22 | 46 | 49 |
Total operating expenses | 60 | 213 | 131 |
Income (loss) from operations | -11 | 138 | -131 |
Interest and Other Income | 0 | 0 | 11 |
Income (loss) before income taxes | - | 139 | -119 |
Income tax benefit (expense) | - | 17 | -4 |
Net income (loss) | -11 | 121 | -116 |
Unrealized loss on available-for-sale investments | - | - | -1 |
Comprehensive income (loss) | - | - | -117 |
Basic | - | 1.46 | -1.39 |
Diluted | - | 1.37 | -1.39 |